Publicacions en col·laboració amb investigadors/es de Universidad de Salamanca (37)

2024

  1. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  2. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

  3. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

    Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284

  4. SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

    Cell Reports, Vol. 43, Núm. 3

  5. Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3

    Biomedicine and Pharmacotherapy, Vol. 180

  6. Strategies to enhance the response of liver cancer to pharmacological treatments

    American journal of physiology. Cell physiology, Vol. 327, Núm. 1, pp. C11-C33

2023

  1. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  2. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  2. Impact of Liver Inflammation on Bile Acid Side Chain Shortening and Amidation

    Cells, Vol. 11, Núm. 24

  3. Impact of alternative splicing variants on liver cancer biology

    Cancers, Vol. 14, Núm. 1

  4. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

  5. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  6. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  2. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  3. Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis

    Molecular Therapy - Methods and Clinical Development, Vol. 22, pp. 210-221

  4. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

2020

  1. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma

    Cancers, Vol. 12, Núm. 6

  2. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

    British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059